Search
SOLACI Congress
Day 3

REDUCE-HTN: safety and efficacy of new bipolar device for renal denervation

solaci
solaci
15
0

This study included 146 patients with resistant hypertension who were medicated with an average of 5.4 drugs. Preliminary 18-month data showed a significant reduction of blood pressure values

Previous article
TITAN-AMI: Final results of bio-active coated stent
Next article
SOURCE XT: Results at 2 years of SAPIEN XT valve
solaci
solaci

More articles by this author

SOURCE XT: Results at 2 years of SAPIEN XT valve

solaci - 0
Multicenter prospective study included 2688 patients with a mean age of 81.4 years and 20.5 EuroScore. The all-cause mortality at 2 years was 27.7%...

NOBORI II: Final 5-year results of drug-eluting stent with bio-absorbable polymer

solaci - 0
This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5...

TRYTON dedicated bifurcation stent in left main coronary artery

solaci - 0
TRYTON is a cobalt chromium device specifically dedicated for bifurcation lesions to be implanted in the side branch. Circumflex artery is the major lateral...

UK TAVI Registry: Long-term results of TAVI in the UK

solaci - 0
This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 3

SOURCE XT: Results at 2 years of SAPIEN XT valve

Multicenter prospective study included 2688 patients with a mean age of 81.4 years and 20.5 EuroScore. The all-cause mortality at...
solaci -
SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Dr. Carlos Fava - 0
Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

solaci - 0
Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Evolution of Small Balloon-Expandable Valves

Dr. Carlos Fava - 0
Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

solaci - 0
Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

Institutional News

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy